Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 10, pp 3088–3095 | Cite as

Trends in the Diagnosis of Phyllodes Tumors and Fibroadenomas Before and After Release of WHO Classification Standards

  • Jenny Chang
  • Laura Denham
  • Eun Kyu Dong
  • Kirollos Malek
  • Sharon S. Lum
Breast Oncology

Abstract

Background

In 2012, the World Health Organization (WHO) released diagnostic criteria for grading phyllodes tumors based on histologic features. This study sought to examine the application of the WHO criteria and the changing epidemiology of fibroepithelial tumors.

Methods

A retrospective review of surgically excised fibroepithelial lesions from 2007 to 2017 at a single tertiary care institution was conducted. Data regarding the WHO criteria (tumor border, stromal cellularity, stromal cell atypia, stromal overgrowth, mitotic activity) and traditional descriptors (leaf-like architecture, periductal stromal condensation) were collected. Clinical and pathologic characteristics of cases with diagnoses determined before and after 2012 were compared.

Results

During the study period, 305 fibroepithelial tumors were identified. No significant differences were observed in terms of mean age, race/ethnicity, presenting symptoms, or method of diagnosis between cases diagnosed before and after 2012. After 2012, the findings showed statistically significant increases in reporting of WHO and traditional histologic features, a decrease in diagnoses of fibroadenomas (85.9% [116/135] before vs 70.0% [119/170] after 2012), and an increase in benign phyllodes tumors (0% [0/135] before vs 12.9% [22/170] after 2012). Patients with a diagnosis of benign phyllodes tumors were significantly younger than those with a diagnosis of borderline, malignant, or non-graded phyllodes tumors (mean age, 25.7 ± 10.6 vs 52.8 ± 9.9, 40.7 ± 24, 46.3 ± 1.5 years, respectively; p = 0.006).

Conclusions

The expanding use of the 2012 WHO criteria has been accompanied by an increased diagnostic frequency of benign phyllodes tumors and a decrease in fibroadenomas. As fibroepithelial diagnoses become more distinct, evidence-based management recommendations for less virulent phyllodes diagnoses should be developed.

Notes

Disclosures

The authors report no financial disclosures

References

  1. 1.
    DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ilvan S. Fibroepithelial tumors of the breast. In: Aydiner A, İğci A, Soran A (eds) Breast disease: diagnosis and pathology. Springer International Publishing, Cham, 2016, pp 283–288.CrossRefGoogle Scholar
  3. 3.
    Klein S. Evaluation of palpable breast masses. Am Fam Physician. 2005;71:1731–8.PubMedGoogle Scholar
  4. 4.
    Lakhani SR EI, Schnitt SJ, Tan PH, van de Vijver MJ (eds). World Health Organization classification of tumours of the breast. Lyon: International Agency for Research on Cancer (IARC); 2012.Google Scholar
  5. 5.
    Lawton TJ, Acs G, Argani P, et al. Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Int J Surg Pathol. 2014;22:695–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Krings G, Bean GR, Chen YY. Fibroepithelial lesions: the WHO spectrum. Semin Diagn Pathol. 2017;34:438–52.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Network NCC. NCCN Clinical Practice Guidelines in Oncology Breast Cancer, version 1, 20 March 2018. Retrieved 15 Apr 2018 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
  8. 8.
    Amin AL, Purdy AC, Mattingly JD, Kong AL, Termuhlen PM. Benign breast disease. Surg Clin North Am. 2013;93:299–308.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. World Health Organization Classification of Tumours. Lyon: World Health Organization; 2003.Google Scholar
  10. 10.
    Rodrigues MF, Truong PT, McKevitt EC, Weir LM, Knowling MA, Wai ES. Phyllodes tumors of the breast: the British Columbia Cancer Agency experience. Cancer Radiother. 2018;22:112–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol. 2014;21:3304–9.CrossRefGoogle Scholar
  12. 12.
    Barrio AV, Clark BD, Goldberg JI, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007;14:2961–70.CrossRefGoogle Scholar
  13. 13.
    Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer. 2000;89:1502–11.CrossRefGoogle Scholar
  14. 14.
    Borhani-Khomani K, Talman ML, Kroman N, Tvedskov TF. Risk of local recurrence of benign and borderline phyllodes tumors: a Danish population-based retrospective study. Ann Surg Oncol. 2016;23:1543–8.CrossRefGoogle Scholar
  15. 15.
    Koh VCY, Thike AA, Tan PH. Distant metastases in phyllodes tumours of the breast: an overview. Appl Cancer Res. 2017;37:15.CrossRefGoogle Scholar
  16. 16.
    Ben Hassouna J, Damak T, Gamoudi A, et al. Phyllodes tumors of the breast: a case series of 106 patients. Am J Surg. 2006;192:141–7.CrossRefGoogle Scholar
  17. 17.
    Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol. 2012;65:69–76.CrossRefGoogle Scholar
  18. 18.
    Slodkowska E, Nofech-Mozes S, Xu B, et al. Fibroepithelial lesions of the breast: a comprehensive morphological and outcome analysis of a large series. Mod Pathol. 2018;  https://doi.org/10.1038/s41379-018-0032-8.CrossRefPubMedGoogle Scholar
  19. 19.
    Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19:2612–7.CrossRefGoogle Scholar
  20. 20.
    Five Things Physicians and Patients Should Question–Benign Breast Disease. Choosing Wisely, 2018. Retrieved 17 Apr 2018 https://www.breastsurgeons.org/docs/ASBrS-Benign_5things%20List.pdf.
  21. 21.
    Greenberg R, Skornick Y, Kaplan O. Management of breast fibroadenomas. J Gen Intern Med. 1998;13:640–5.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kaufman CS, Bachman B, Littrup PJ, et al. Office-based ultrasound-guided cryoablation of breast fibroadenomas. Am J Surg. 2002;184:394–400.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Yasir S, Gamez R, Jenkins S, Visscher DW, Nassar A. Significant histologic features differentiating cellular fibroadenoma from phyllodes tumor on core needle biopsy specimens. Am J Clin Pathol. 2014;142:362–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Moo TA, Alabdulkareem H, Tam A, et al. Association between recurrence and reexcision for close and positive margins versus observation in patients with benign phyllodes tumors. Ann Surg Oncol. 2017;24:3088–92.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Van Osdol AD, Landercasper J, Andersen JJ, et al. Determining whether excision of all fibroepithelial lesions of the breast is needed to exclude phyllodes tumor: upgrade rate of fibroepithelial lesions of the breast to phyllodes tumor. JAMA Surg. 2014;149:1081–5.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Marcil G, Wong S, Trabulsi N, et al. Fibroepithelial breast lesions diagnosed by core needle biopsy demonstrate a moderate rate of upstaging to phyllodes tumors. Am J Surg. 2017;214:318–22.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wiratkapun C, Piyapan P, Lertsithichai P, Larbcharoensub N. Fibroadenoma versus phyllodes tumor: distinguishing factors in patients diagnosed with fibroepithelial lesions after a core needle biopsy. Diagn Interv Radiol. 2014;20:27–33.PubMedGoogle Scholar
  28. 28.
    Tan BY, Acs G, Apple SK, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 2016;68:5–21.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yang X, Kandil D, Cosar EF, Khan A. Fibroepithelial tumors of the breast: pathologic and immunohistochemical features and molecular mechanisms. Arch Pathol Lab Med. 2013;138:25–36.CrossRefGoogle Scholar
  30. 30.
    Cerrato F, Labow BI. Diagnosis and management of fibroadenomas in the adolescent breast. Semin Plast Surg. 2013;27:23–5.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Jayasinghe Y, Simmons PS. Fibroadenomas in adolescence. Curr Opin Obstet Gynecol. 2009;21:402–6.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer. 1996;77:910–16.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw. 2007;5:324–30.CrossRefGoogle Scholar
  34. 34.
    Shaaban M, Barthelmes L. Benign phyllodes tumours of the breast: (Over) treatment of margins: a literature review. Eur J Surg Oncol. 2017;43:1186–90.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Jenny Chang
    • 1
  • Laura Denham
    • 2
  • Eun Kyu Dong
    • 1
  • Kirollos Malek
    • 1
  • Sharon S. Lum
    • 1
  1. 1.Department of Surgery, Division of Surgical OncologyLoma Linda University School of MedicineLoma LindaUSA
  2. 2.Department of PathologyLoma Linda University School of MedicineLoma LindaUSA

Personalised recommendations